Clinical Significance of HER2‐low Expression in Triple‐ negative Breast Cancer: A Retrospective Multicenter Study
Although the HER2-low and HER2-null tumor groups among TNBC showed no significant differences in response to neoadjuvant chemotherapy or patient outcomes, the higher proliferative activity and differing outcome trends in HER2-null tumors suggest possible biological differences.
Authors
- Kimito Yamada (ORCID: https://orcid.org/0000-0002-5443-7078)
- Kazutaka Narui (ORCID: https://orcid.org/0000-0002-0135-5001)
- Mina Iwai (ORCID: https://orcid.org/0000-0002-4725-9664)
- Keigo Amaya
- Akimitsu Yamada (ORCID: https://orcid.org/0000-0003-3006-0648)
- Takashi Ishikawa (ORCID: https://orcid.org/0000-0003-3450-4533)
- Yoshiya Horimoto (ORCID: https://orcid.org/0000-0001-8935-0768)
- Rongrong Wu (ORCID: https://orcid.org/0000-0003-1256-4543)
- Hiroshi Kaise (ORCID: https://orcid.org/0000-0002-6638-783X)
Institutions
- Yokohama City University Medical Center (JP)
- Tokyo Medical University Hachioji Medical Center (JP)
- Tokyo Medical University Hospital (JP)
- Yokohama City University (JP)
Publication Details
- Journal
- Cancer Diagnosis & Prognosis
- Published
- 2025-07-01
- DOI
- https://doi.org/10.21873/cdp.10463
- Citations
- 1
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 1.05